Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-β/activin receptor-like kinase-4/5/7/Smad2 signaling pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 431-438

  Ruiz, Emilio ^a   Redondo, Santiago ^a   Gordillo Moscoso, Antonio ^a   Tejerina, Teresa ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; DNA FRAGMENT; PIOGLITAZONE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETIC PATIENT; DNA DETERMINATION; DRUG EFFECT; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; VASCULARIZATION;

ACTIVIN RECEPTORS; ACTIVIN RECEPTORS, TYPE I; AGED; APOPTOSIS; ATHEROSCLEROSIS; CELLS, CULTURED; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PPAR GAMMA; PROTEIN-TYROSINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34247194273     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.114934     Document Type: Article

References (33)

1. Aizawa Y, Kawabe J, Hasebe N, Takehara N, and Kikuchi K (2001) Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104:455-460.
2. American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28:S37-S42.
3. Bishop-Bailey D, Hla T, and Warner TD (2002) Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-γ ligand therapy. Circ Res 91:210-213.
4. Boitier E, Gautier JC, and Roberts R (2003) Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol 2:3-5.
5. Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, and Grainger DJ (1998) Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis 140:45-53.
6. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, and Eckland D (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-374.
7. Corton C, Anderson SP, and Stauber A (2000) Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40:491-518.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289.
9. Dunaif A, Scott A, Finegood D, Quintana B, and Whitcomb R (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306.
10. Fajas L, Debril MB, and Auwerx J (2001) Peroxisome proliferator-activated receptorgamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1-9.
11. Gibbons GH and Dzau VJ (1994) The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438.
12. Goke B and German Pioglitazone Study Group (2002) Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 1:329-336.
13. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, and Sachinidis A (2001) Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn-Schmiedeberg's Arch Pharmacol 363:215-221.
14. Guan Y, Zhang Y, and Breyer MD (2002) The role of PPARs in the transcriptional control of cellular processes. Drug News Perspect 15:147-154.
15. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, and Hill CS (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74.
16. Ivanov VO, Rabovsky AB, Ivanova SV, and Niedzwiecki A (1998) Transforming growth factor-beta 1 and ascorbate regulate proliferation of cultured smooth muscle cells by independent mechanisms. Atherosclerosis 140:25-34.
17. Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, Tararak E, and Bobik A (2004) Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol 2004:1391-1396.
18. Kannan K, Amariglio N, Rechavi G, Givol D, Yoo J, Ghiassi M, Jirmanova L, Balliet AG, Hoffman B, Fornace AJ Jr, et al. (2003) Transforming growth factor-β-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem 278:43001-43007.
19. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, and Nakamura Y (2001) Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456.
20. Lin Y, Zhu X, McLntee FL, Xiao H, Zhang J, Fu M, and Chen YE (2004) Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24:257-263.
21. O'Neil CH, Boffa MB, Hancock MA, Pickering JG, and Koschinsky ML (2004) Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein. (a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem 279:55187-55195.
22. Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, and Spandidos DA (2005) Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 15: 603-610.
23. Pfeiffer A, Middelberg-Bisping K, Drewes C, and Schatz H (1996) Elevated plasma levels of transforming growth factor-β1 in NIDDM. Diabetes Care 19:1113-1117.
24. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, and Forst T (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925-1931.
25. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, and Tejerina T (2005) Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 54:811-817.
26. Ruiz E, Gordillo-Moscoso A, Redondo S, Rodriguez E, Reguillo F, Briones AM, Van Breemen C, Okon E, and Tejerina T (2006) Human vascular smooth muscle cells from diabetic patients are resistant to induced apoptosis due to high Bcl-2 expression. Diabetes 55:1243-1251.
27. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, and Chen CS (2005) Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 15:1561-1569.
28. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, et al. (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:E5.
29. Ten Dijke P, Goumans M-J, Itoh F, and Itoh S (2002) Regulation of cell proliferation by Smad proteins. J Cell Physiol 191:1-16.
30. Ten Dijke P and Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29:265-273.
31. Terry JG, Tang R, Espeland MA, Davis DH, Vieira JL, Mercuri MF, and Crouse JR (2003) Carotid structure in patients with documented coronary artery disease and disease-free control subjects. Circulation 107:1146-1151.
32. United Kingdom Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865.
33. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, and Kiyosawa K (2002) Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95:2243-2251.